Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Locally Advanced Breast Cancer
Interventions: DRUG: Palbociclib
Sponsor: Consorzio Oncotech